CEO's suspension only a small bump in TalkMed's longer-term outlook, says RHB
Michelle Zhu • • 2 min read
SINGAPORE (Nov 8): RHB has downgraded its call on TalkMed Group to “neutral” from “buy” previously while raising its target price from 69 cents to 72 cents, which implies 29 times FY18F P/E.
Follow us on Facebook and join our Telegram channel for the latest updates.
SINGAPORE (Nov 8): RHB has downgraded its call on TalkMed Group to “neutral” from “buy” previously while raising its target price from 69 cents to 72 cents, which implies 29 times FY18F P/E.
This comes even after the group reported better-than-expected 3Q17 results after mitigating impacts from the suspension of CEO Dr Ang Peng Tiam by the Singapore Medical Council (SMC), such that 3Q17 NPAT only dropped 17.2% y-o-y.
Never miss out on important financial news and get daily updates today
×
Download The Edge Singapore App
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
